The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …
This new report provides strategic directions of global diagnostic imaging companies. The report presents insightful strategic assessments, including:
- Business, new product development, and marketing strategies.
- Anticipated acquisitions, joint ventures, and divestitures.
The companies analyzed in the report include Analogic, Esaote, GE, Hitachi/Aloka, Hologic, Philips, Shimadzu, Siemens, and Toshiba.